Sangiovanni A. et al. (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology, 126(4):1005-14.
Burroughs A. & McNamara D. (2003) Liver disease in Europe. Alimentary Pharmacology & Therapeutics, 18:54–59.
Smart R.G. Mann R.E. (1992) Alcohol and the epidemiology of liver cirrhosis. Alcohol Health Res World. 16:217-222.
Klatsky A.L. Armstrong M.A. Friedman G.D. (1993) Coffee, tea, and mortality. Ann Epidemiol. Jul;3(4):375-81.
Bravi F. et al. (2007) Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology, 46:430-435.
Larsson S.C. et al. (2007) Coffee consumption and liver cancer: a meta-analysis. Gastroenterology, 132:1740-1745.
Bravi F. et al. (2013) Coffee reduces risk for hepatocellular carcinoma: An updated meta-analysis. Clinical Gastroenterology and Hepatology, 11:1413-1421.
Leung W.W. et al. (2011) Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. Journal of Epidemiology & Community Health, 65:556-558.
Jang E.S. et al. (2013) The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area. Liver International, 33(7):1092-1099.
Lai G.Y. (2013) The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. British Journal of Cancer 109:1344–1351.
Setiawan V.W. et al (2014) Association of Coffee Intake with Reduced Incidence of Liver Cancer and Death from Chronic Liver Disease in the US Multiethnic Cohort, Gastroenterology, published online ahead of print. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25305507
Saab S. et al. (2014) Impact of coffee on liver disease a systematic review. Liver International 34(4):495-504.
Gressner O.A. (2009) About coffee, cappuccino and connective tissue growth factor – or how to protect your liver!? Environmental Toxicology and Pharmacology, 28(1):1-10.
Modi A.A. et al. (2010) Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology, 51:201-209.
Xiao Q. et al. (2014) Inverse association of total and decaffeinated coffee with liver enzymes in NHAMES 1999-2010. Hepatology, published online ahead of print. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25124935
Stroffolini T. et al. (2010) Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver International, 30(6):867-870.
Walton H.B. et al. (2013) An epidemiological study of the association of coffee with chronic liver disease. Scottish Medical Journal, 58(4):217-222.
Catalano D. et al. (2010) Protective role of coffee on non-alcoholic fatty liver disease (NAFLD). Digestive Disease and Sciences, 55(11):3200-3206.
Birerdinc A. et al. (2012) Caffeine is protective in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 35(1):76-82.
Molloy J.W. et al. (2012) Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology, 55(2):429-36.
Gutierrez-Grobe Y. et al. (2012) High coffee intake is associated with lower grade non-alcoholic fatty liver disease: the role of peripheral antioxidant activity. Annals of Hepatology, 11(3):350-355.
Bambha K. et al. (2014) Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver International. 34(8):1250-8.
Freedman N.D. et al. (2009) Coffee intake is associated with lower rates of liver disease progression in chronic Hepatits-C. Hepatology, 50:1360–9.
Costentin C.E. et al. (2011) Association of caffeine intake and histological features of chronic hepatitis C. Journal of Hepatology, Volume 54; 1123-1129.
Sasaki Y. et al. (2014) Effect of caffeine containing beverage consumption on serum alanine aminotransferase levels in patients with chronic hepatitis C virus infection: a hospital based cohort study. PLoS One, 8(12): e83382. Published online Dec 11, 2013. doi: 1371/journal.pone.0083382
Goh G.B. et al. (2014) Coffee, alcohol, and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology, 60:661-9.
Gressner O.A. (2009) Less Smad2 is good for you? A scientific update on coffee’s liver benefits. Hepatology, 50, 970-978.
Gressner O.A. et al. (2009) Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in parenchymal cells. Liver International, 29(6):886-897.
Muriel P. et al. (2010) Coffee and liver disease. Fitoterapia, 81:297-305.
Wang G.W. et al. (2009) Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Research, 83(2):186-90.
Tiedot on suunnattu terveydenhuollon ammattilaisille ja ravitsemusasiantuntijoille.